Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar
Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...
| Autores principales: | , , , |
|---|---|
| Formato: | Journal article |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|